Atualizações sobre a fertilização in vitro para reprodução humana / Updates on in vitro fertilization for human reproduction
DOI:
https://doi.org/10.34119/bjhrv5n1-269Keywords:
Fertilização In Vitro, Fertilização, Embrião, Laboratório.Abstract
A fertilização in vitro se refere a um procedimento projetado para superar a infertilidade e produzir uma gravidez como resultado direto da intervenção, em geral, os ovários são estimulados por uma combinação de medicamentos para fertilidade e, em seguida, um ou mais oócitos são aspirados dos folículos ovarianos. Os fatores mais importantes relacionados ao procedimento que afetam o sucesso são o número de oócitos recuperados e o número de embriões de alta qualidade derivados deles no laboratório, os embriões fertilizados em excesso daqueles que podem ser transferidos com segurança podem ser criopreservados indefinidamente para uso futuro. Em uma base por ciclo, por causa da transferência de vários embriões, os resultados do tratamento de fertilização in vitro agora excedem ligeiramente a fecundabilidade dos ciclos de concepção natural na população em geral. A principal razão para o fracasso em conseguir gravidez com fertilização in vitro é a falta de implantação devido à baixa qualidade do embrião, baixa receptividade endometrial ou baixa eficiência de transferência de embriões.
References
Steptoe PC, Edwards RG. Reimplantation of a human embryo with subsequent tubal pregnancy. Lancet 1976; 1:880.
Dupree JM, Levinson Z, Kelley AS, et al. Provision of Insurance Coverage for IVF by a Large Employer and Changes in IVF Rates Among Health Plan Enrollees. JAMA 2019; 322:1920.
Ledger WL, Anumba D, Marlow N, et al. The costs to the NHS of multiple births after IVF treatment in the UK. BJOG 2006; 113:21.
Chinnery PF. Mitochondrial Replacement in the Clinic. N Engl J Med 2020; 382:1855.
Toner JP, Philput CB, Jones GS, Muasher SJ. Basal follicle-stimulating hormone level is a better predictor of in vitro fertilization performance than age. Fertil Steril 1991; 55:784.
Paulson RJ, Marrs RP. Ovulation stimulation and monitoring for in vitro fertilization. Curr Probl Obstet Gynecol Infert 1986; 10:497.
Shapiro BS, Daneshmand ST, Garner FC, et al. Contrasting patterns in in vitro fertilization pregnancy rates among fresh autologous, fresh oocyte donor, and cryopreserved cycles with the use of day 5 or day 6 blastocysts may reflect differences in embryo-endometrium synchrony. Fertil Steril 2008; 89:20.
Maheshwari A, Gibreel A, Siristatidis CS, Bhattacharya S. Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database Syst Rev 2011; :CD006919.
Abou-Setta AM, Peters LR, D'Angelo A, et al. Post-embryo transfer interventions for assisted reproduction technology cycles. Cochrane Database Syst Rev 2014; :CD006567.
Stern JE, Lieberman ES, Macaluso M, Racowsky C. Is cryopreservation of embryos a legitimate surrogate marker of embryo quality in studies of assisted reproductive technology conducted using national databases? Fertil Steril 2012; 97:890.
Allersma T, Farquhar C, Cantineau AE. Natural cycle in vitro fertilisation (IVF) for subfertile couples. Cochrane Database Syst Rev 2013; :CD010550.
Licciardi FL, Liu HC, Rosenwaks Z. Day 3 estradiol serum concentrations as prognosticators of ovarian stimulation response and pregnancy outcome in patients undergoing in vitro fertilization. Fertil Steril 1995; 64:991.
Maheshwari A, Fowler P, Bhattacharya S. Assessment of ovarian reserve--should we perform tests of ovarian reserve routinely? Hum Reprod 2006; 21:2729.
Arce JC, La Marca A, Mirner Klein B, et al. Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients. Fertil Steril 2013; 99:1644.
Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e691S.
Youssef MA, Van der Veen F, Al-Inany HG, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev 2014; :CD008046.
Arslan M, Bocca S, Mirkin S, et al. Controlled ovarian hyperstimulation protocols for in vitro fertilization: two decades of experience after the birth of Elizabeth Carr. Fertil Steril 2005; 84:555.
Kroon B, Hart RJ, Wong BM, et al. Antibiotics prior to embryo transfer in ART. Cochrane Database Syst Rev 2012; :CD008995.
Boulet SL, Mehta A, Kissin DM, et al. Trends in use of and reproductive outcomes associated with intracytoplasmic sperm injection. JAMA 2015; 313:255.
De Croo I, Colman R, De Sutter P, Tilleman K. Blastocyst transfer for all? Higher cumulative live birth chance in a blastocyst-stage transfer policy compared to a cleavage-stage transfer policy. Facts Views Vis Obgyn 2019; 11:169.
Nastri CO, Lensen SF, Gibreel A, et al. Endometrial injury in women undergoing assisted reproductive techniques. Cochrane Database Syst Rev 2015; :CD009517.
Smith AD, Tilling K, Nelson SM, Lawlor DA. Live-Birth Rate Associated With Repeat In Vitro Fertilization Treatment Cycles. JAMA 2015; 314:2654.
Cesta CE, Johansson ALV, Hreinsson J, et al. A prospective investigation of perceived stress, infertility-related stress, and cortisol levels in women undergoing in vitro fertilization: influence on embryo quality and clinical pregnancy rate. Acta Obstet Gynecol Scand 2018; 97:258.
